Royal Philips has signed a strategic collaboration agreement with a MedTech stroke care company, NICO.LAB to enhance outcomes in stroke patients.

The agreement will complement the extended stroke capabilities of Philips’ image-guided therapy system, Azurion.

With an extensive portfolio of stroke care solutions, Philips will use NICO.LAB’s StrokeViewer solution to streamline the stroke workflow and enhance outcomes in patients.

StrokeViewer is a Cloud-based, end-to-end artificial intelligence (AI)-driven stroke triage and management platform which assesses computerised tomography (CT) scan data using AI and identifies large vessel occlusion and its position.

The solution can also share the analysis with doctors at primary stroke centres as well as intervention centres.

The latest innovations of Philips’ Image-Guided Therapy Angiography Suite with 3D visualisation and measurement tool, SmartCT, help patients to receive treatment rapidly.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Furthermore, Philips is studying a new method to expedite stroke treatment for early time-window stroke patients, which falls under six hours of stroke onset. This approach involves bypass of diagnostic CT or magnetic resonance (MR) scans at specific types of stroke centres.

Meanwhile, Philips enrolled the first subject in the WE-TRUST clinical trial, which will evaluate the effect of a Direct to Angio Suite workflow on advancing stroke patient care.

This technique can aid in fast patient routing while the use of the SmartCT imaging features of the Azurion Angio Suite can enable additional diagnoses to confirm treatment eligibility.

The multi-centre, randomised, controlled, prospective, open-label, blinded-endpoint WE-TRUST trial will enol a total of 564 subjects at 15 centres globally.

Royal Philips image-guided therapy chief business leader Bert van Meurs said: “By expanding our offerings in stroke care we are able to provide an integrated portfolio of intelligent solutions across the full stroke care pathway, giving clinicians the right information during every critical step.

“With our integrated portfolio, and by using validated AI and Cloud technologies, we can facilitate collaborative care to optimise the stroke care pathway from diagnosis to treatment.”

Last week, Philips and the Spanish National Center for Cardiovascular Research started a collaborative research project for creating a new cardiac MR imaging technique.